Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Fludesoxiglucosa (18F)-Curium 185 MBq/ml, soluciΓ³n inyectable
The George Institute
Cardiovascular device infections
1 trial -
Foliumzuur Aurobindo 5 mg, tabletten, XELJANZ 5 mg film-coated tablets, METHOTREXAAT SANDOZ 2,5 MG, TABLETTEN, Methotrexaat Teva 20,0 mg, Oplossing voor injectie in een voorgevulde pen, Enbrel 50 mg solution for injection in pre-filled syringe, Methotrexaat Teva 25,0 mg, Oplossing voor injectie in een voorgevulde pen, Methotrexaat Teva 15 mg, Oplossing voor injectie in een voorgevulde pen
Disc Medicine
Psoriatic arthritis
1 trial -
Formoterol
Pacira Ireland Limited
Chronic Obstructive Pulmonary Disease
1 trial -
GEMCITABINE HYDROCHLORIDE, CISPLATIN, AVELUMAB, CISPLATIN, CISPLATIN, CISPLATIN, CARBOPLATIN, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE
Fondazione Telethon ETS
metastatic or locally advanced urothelial cancer
1 trial -
Gadoxetate disodium
Guerbet
Motor Function
1 trial -
Ganciclovir
Hoffmann-La Roche
Cytomegalovirus Infections
1 trial -
Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
The George Institute
Evaluation of the reduction of HPV infectivity and transmission before and after vaccination with 9vHPV
1 trial -
Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Pierre Fabre Australia Pty Ltd
giving a commercially available vaccine to women with HIV under treatment, women living with HIV traeted by antiretroviral
1 trial -
Group 1 Standard of Care
Pacira Ireland Limited
Retraction of Colostomy
1 trial -
Guanfacine hydrochloride (TAK-503)
Takeda
Attention Deficit Hyperactivity Disorder
1 trial -
Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL
Janssen-Cilag International N.V.
Psoriatic Arthritis
1 trial -
H1N1 influenza A Vaccine (Split virion), Inactivated
Sinovac Research and Development Co.,
Influenza
1 trial -
HALOPERIDOL, CLOZAPINE, TIAPRIDE, SERTINDOLE, PALIPERIDONE, OLANZAPINE, SULPIRIDE, ARIPIPRAZOLE, LURASIDONE, RISPERIDONE, AMISULPRIDE, CHLORPROMAZINE, PIMOZIDE, QUETIAPINE
Disc Medicine
HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose reduction/discontinuation.
1 trial -
HYDROXYCHLOROQUINE , ABATACEPT , AZATHIOPRINE , SULFASALAZINE , METHOTREXATE , Cimzia 200 mg solution for injection in pre-filled syringe, LEFLUNOMIDE, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISOLONE , Triamcinolone Hexacetonide 20 mg/ml suspension for injection, METHOTREXATE
The George Institute
Rheumatoid Arthritis
1 trial -
Healive (hepatitis A vacine(human diploid cell), inactivated)
Sinovac Research and Development Co.,
Hepatitis A
1 trial -
Hemlibra 150 mg/mL solution for injection
Hoffmann-La Roche
Severe or Moderate Hemophilia A
1 trial -
Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection
Disc Medicine
Congenital Haemophilia A
1 trial -
Hiconcil 500 mg trde kapsule, Enterol 250 mg, gΓ©lules, Matched Placebo will consist in caspules similar to the 250 mg capsules of the Saccharomyces boulardii CNCM-I-745 but with no active ingredient
Biocodex
Patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis))
1 trial -
High-dosage of COVID-19 vaccine (Vero cell), Inactivated
Sinovac Research and Development Co.,
COVID-19
1 trial -
Humira 40 mg solution for injection in pre-filled pen, ORENCIA 125 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, ORENCIA 250 mg powder for concentrate for solution for infusion, Cosentyx 150 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Jylamvo 2 mg/ml oral so
Istituto Gentili S.r.l.
Juvenile idiopathic arthritis
1 trial -
Hyperbaric bupivacaine+Sufentanil
Lxo Ireland Designated Activity Company
Anesthesia; Functional
1 trial -
INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN
The George Institute
Influenza, Immunity against influenza
1 trial -
IV morphine sulfate
Pacira Ireland Limited
Bowel Obstruction
2 trials -
IV morphine sulfate or Sponsor-approved equivalent
Pacira Ireland Limited
Retraction of Colostomy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources